Advertisement
FDMT vs RCKT
Which Stock Would AI Choose? 4D Molecular Therapeutics (FDMT) vs. Rocket Pharmaceuticals (RCKT) Stock Comparison
Key Takeaways
- FDMT is a clinical-stage gene therapy company focused on ophthalmology and pulmonology, while RCKT is a gene therapy developer targeting rare cardiovascular and hematologic disorders.
- FDMT trades at a higher share price and larger market capitalization than RCKT, though both remain pre-profitability biotech names with binary clinical catalysts ahead.
- FDMT's value centers on its lead candidate 4D-150 for wet AMD, whereas RCKT's near-term story revolves around the approved Kresladi therapy and the pivotal Danon disease program.
- RCKT has seen renewed analyst attention following FDA alignment and a $150 million credit facility, while FDMT carries a broader "Strong Buy" consensus with a higher average price target.
- For more detail on each company, explore FDMT Major News and FDMT Today's Price Move, as well as RCKT Major News and RCKT Today's Price Move.
- To see how AI evaluates market opportunities across these and other tickers, explore Trending AI Robots.
Introduction
This stock comparison examines two clinical-stage gene therapy developers: 4D Molecular Therapeutics (FDMT) and Rocket Pharmaceuticals (RCKT). Both companies operate in the high-risk, high-reward biotechnology sector, where valuations hinge on clinical trial outcomes and regulatory decisions rather than near-term earnings. The comparison is particularly relevant for investors and traders evaluating relative performance and market positioning among gene therapy names, where capital efficiency, pipeline depth, and catalyst timing often drive sentiment more than current revenue. Understanding how these two firms differ in therapeutic focus and financial footing can help frame a more informed view of sector opportunities.
FDMT Overview and Recent Performance
4D Molecular Therapeutics is a clinical-stage biotechnology company headquartered in Emeryville, California, specializing in targeted gene therapies developed through its proprietary vector evolution platform. The company's lead candidate, 4D-150, is being studied for wet age-related macular degeneration (AMD) and diabetic macular edema, with pivotal Phase 3 data for wet AMD expected in 2027. The pipeline also includes 4D-710 for cystic fibrosis and programs for Fabry disease.
In recent weeks, FDMT's shares have traded in a range well below their 52-week high, with a market capitalization of roughly $700 million. Recent market activity has been shaped by analyst updates, including price-target adjustments, and by a strategic partnership with Otsuka that provided an $85 million upfront payment and cost-sharing support. Wall Street maintains a broadly favorable consensus on FDMT, with a "Strong Buy" rating and an average price target well above current levels, reflecting expectations tied to the 4D-150 data readout. However, ongoing operating losses and insider selling activity have contributed to mixed near-term sentiment.
RCKT Overview and Recent Performance
Rocket Pharmaceuticals is a biotechnology company focused on gene therapies for rare and devastating diseases, with particular emphasis on cardiovascular and hematologic conditions. Its most advanced asset, Kresladi (marnetegragene autotemcel), received FDA accelerated approval in 2026 for severe leukocyte adhesion deficiency-I (LAD-I), an ultra-rare genetic disorder. The company's lead investigational program, RP-A501, is in a pivotal Phase 2 study for Danon disease, a rare inherited heart condition.
RCKT has experienced renewed attention in recent weeks following a series of notable developments. The FDA confirmed the company could continue dosing patients in the Phase 2 Danon study at a recalibrated dose, an outcome analysts described as removing a "meaningful regulatory overhang." Rocket also secured access to a $150 million credit facility with Hercules Capital to fund its cardiovascular pipeline. These events triggered upgrades from firms such as Needham and a price-target increase from Goldman Sachs. Despite this, RCKT trades at a relatively low share price and modest market capitalization, reflecting the early stage of its commercial trajectory.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI trading bots drawn from a larger universe of hundreds of automated strategies that collectively trade thousands of different tickers. Not every bot earns a place in this section; only those best suited to current market conditions are featured, giving traders a filtered view of strategies that align with today's environment. These bots vary widely in trading style, strategy, timeframe, performance history, statistics, and the specific tickers they trade, so investors can evaluate options that match their own approach to risk and holding periods. The page offers an accessible way to observe how AI-driven systems analyze momentum, trend, and volatility across the market. For those interested in exploring automated, data-driven trading ideas, visiting Trending AI Robots may provide useful perspective.
Head-to-Head Comparison
While both companies are gene therapy developers, their business models and growth drivers differ meaningfully. FDMT is concentrated on ophthalmology, pursuing a large addressable market in wet AMD through a single lead candidate that targets reduced injection burden. RCKT, by contrast, spans a broader but smaller, ultra-rare disease portfolio across cardiovascular and hematologic indications.
In terms of recent momentum and market positioning, FDMT commands a substantially larger market capitalization and higher share price, supported by a "Strong Buy" analyst consensus. RCKT trades at a fraction of FDMT's valuation, with a more mixed analyst spread of buy, hold, and sell ratings, though recent upgrades signal improving sentiment.
Risk factors also differ. FDMT's thesis depends heavily on a single pivotal data readout expected in 2027, creating concentrated binary risk. RCKT carries its own clinical and regulatory risk, having previously faced a clinical hold on its Danon program, though it now benefits from one FDA-approved product and a strengthened balance sheet.
On financial strength, FDMT has historically maintained a larger cash position and a partnering arrangement that extends its runway, while RCKT recently bolstered its finances through a credit facility and voucher sale. Neither company is yet profitable, so capital efficiency remains central to both narratives.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalyst visibility, and relative positioning, Tickeron's AI would likely favor FDMT in the current environment. The company's larger market capitalization, broader analyst consensus, established strategic partnership, and clearly defined near-term catalyst in its lead program contribute to a relatively more stable and positive technical and fundamental profile. RCKT has shown encouraging momentum following regulatory alignment and financing announcements, but its smaller scale and more varied analyst outlook suggest a less consistent trend at present. This assessment reflects probabilistic positioning rather than a definitive forecast, and either stock's trajectory could shift materially with new clinical data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FDMT is a Buy and RCKT is a Hold.
FDMT sees its Stochastic Oscillator recovers from oversold territory
On October 28, 2026, the Stochastic Oscillator for FDMT moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 57 instances where the indicator left the oversold zone. In 48 of the 57 cases the stock moved higher in the following days. This puts the odds of a move higher at over 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FDMT's RSI Oscillator exited the oversold zone, 22 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on FDMT as a result. In 72 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for FDMT just turned positive on October 29, 2026. Looking at past instances where FDMT's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
Following a +10.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where FDMT advanced for three days, in 217 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
FDMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for FDMT crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FDMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FDMT entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.660) is normal, around the industry mean (3.498). P/E Ratio (-4.658) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.662) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. FDMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FDMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
RCKT in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 16, 2026
RCKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 39 cases where RCKT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RCKT's RSI Oscillator exited the oversold zone, 31 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for RCKT just turned positive on October 20, 2026. Looking at past instances where RCKT's MACD turned positive, the stock continued to rise in 41 of 50 cases over the following month. The odds of a continued upward trend are 82%.
Following a +5.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCKT advanced for three days, in 201 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 58 cases where RCKT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RCKT as a result. In 71 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCKT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for RCKT entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.710) is normal, around the industry mean (3.498). P/E Ratio (-14.906) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. RCKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
FDMT | RCKT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 19 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 25 Undervalued | 11 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 92 | |
PRICE GROWTH RATING 1..100 | 46 | 73 | |
P/E GROWTH RATING 1..100 | 59 | 15 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RCKT's Valuation (11) in the Biotechnology industry is in the same range as FDMT (25) in the null industry. This means that RCKT’s stock grew similarly to FDMT’s over the last 12 months.
RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as FDMT (100) in the null industry. This means that RCKT’s stock grew similarly to FDMT’s over the last 12 months.
RCKT's SMR Rating (92) in the Biotechnology industry is in the same range as FDMT (97) in the null industry. This means that RCKT’s stock grew similarly to FDMT’s over the last 12 months.
FDMT's Price Growth Rating (46) in the null industry is in the same range as RCKT (73) in the Biotechnology industry. This means that FDMT’s stock grew similarly to RCKT’s over the last 12 months.
RCKT's P/E Growth Rating (15) in the Biotechnology industry is somewhat better than the same rating for FDMT (59) in the null industry. This means that RCKT’s stock grew somewhat faster than FDMT’s over the last 12 months.
| FDMT | RCKT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 79% | 1 day ago 79% |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 86% |
| Momentum ODDS (%) | 1 day ago 81% | 1 day ago 89% |
| MACD ODDS (%) | 1 day ago 83% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 79% |
| Advances ODDS (%) | 3 days ago 83% | 8 days ago 80% |
| Declines ODDS (%) | 10 days ago 84% | 6 days ago 87% |
| BollingerBands ODDS (%) | 1 day ago 78% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FDMT’s FA Score shows that 1 FA rating(s) are green while RCKT’s FA Score has 2 green FA rating(s).
- FDMT’s FA Score: 1 green, 4 red.
- RCKT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FDMT’s TA Score shows that 6 TA indicator(s) are bullish while RCKT’s TA Score has 4 bullish TA indicator(s).
- FDMT’s TA Score: 6 bullish, 3 bearish.
- RCKT’s TA Score: 4 bullish, 4 bearish.
Price Growth
FDMT (@Biotechnology) experienced а +4.27% price change this week, while RCKT (@Biotechnology) price change was -4.98% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
FDMT is expected to report earnings on Feb 26, 2027.
RCKT is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
FDMT and
Correlation & Price change
A.I.dvisor indicates that over the last year, FDMT has been loosely correlated with KYTX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if FDMT jumps, then KYTX could also see price increases.
| Ticker / NAME | Correlation To FDMT | 1D Price Change % | ||
|---|---|---|---|---|
| FDMT | 100% | +4.25% | ||
| KYTX - FDMT | 59% Loosely correlated | +0.79% | ||
| PRME - FDMT | 55% Loosely correlated | +10.26% | ||
| RCKT - FDMT | 55% Loosely correlated | +1.22% | ||
| EDIT - FDMT | 54% Loosely correlated | -4.99% | ||
| SLDB - FDMT | 54% Loosely correlated | +6.00% | ||
More | ||||
RCKT and
Correlation & Price change
A.I.dvisor indicates that over the last year, RCKT has been loosely correlated with SANA. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RCKT jumps, then SANA could also see price increases.
| Ticker / NAME | Correlation To RCKT | 1D Price Change % | ||
|---|---|---|---|---|
| RCKT | 100% | +1.22% | ||
| SANA - RCKT | 56% Loosely correlated | -5.76% | ||
| EDIT - RCKT | 56% Loosely correlated | -4.99% | ||
| DYN - RCKT | 55% Loosely correlated | +0.39% | ||
| FDMT - RCKT | 55% Loosely correlated | +4.25% | ||
| SLDB - RCKT | 55% Loosely correlated | +6.00% | ||
More | ||||